Symptom complaints of 118 patients with mild traumatic brain injury (MTBI), within 1 month postinjury, were compared with those of 118 control participants without a MTBI. The MTBI and control subjects were group-matched on age, gender, socioeconomic status (SES), and education status. Differences in symptom endorsements and severity ratings were found between the groups, with 16 of the 43 queried symptoms endorsed significantly more often (Bonferroni-corrected P < .00116) by MTBI patients than by controls. A total of 23 of the 43 symptoms were endorsed at a significantly higher severity by MTBI patients. The MTBI sample showed significantly higher withingroup variability, with severity ranging from minimal to high. Perhaps because of this high variability, a logistic regression used to discriminate MTBI patients from controls was only moderately successful. This indicates that subjective complaints probably cannot be used, even soon after injury, to decisively distinguish individual MTBI patients from uninjured persons. D
Introduction
The incidence of mild traumatic brain injury (MTBI) in the general population is at least 130 cases per 100,000 persons (Annegers et al., 1980; Kraus & Nourjah, 1989; Rimel, Girodani, Barth, Boll, & Jane, 1981) . Commonly reported sequelae of MTBI include various emotional, cognitive, and physical symptoms (Alexander, 1995; Gasquoine, 1997) . The NIH Consensus Development Panel on Rehabilitation of Persons With Traumatic Brain Injury (1999) noted that MTBI places substantial burden on society due to its primary (e.g., medical costs) and secondary effects (e.g., loss of productivity). Though many studies have investigated self-report symptoms occurring several months or later after a MTBI, few studies have focused on self-report symptoms within 1 month postinjury. Indeed, only one study was located which compared self-reported postconcussion symptoms with control subjects' self-reports within 1 month of the injury. Dikmen, McLean and Temkin (1986) reported rates of endorsement of 12 symptoms 1 month postinjury for 20 MTBI survivors and 20 uninjured control participants. They found that symptom endorsement was higher for the MTBI group for 11 of the 12 symptoms, but statistical significance was only achieved for three of these symptoms (i.e., bothered by noise, insomnia, and memory difficulties). The small number of statistically significant differences between the groups appears related to the small sample size of the groups. Some of the symptoms not attaining statistical significance appeared to differ by 20% or more on a bar chart showing group endorsement levels.
Other studies assessing post-MTBI complaints have either not reported on specific symptoms, or did not include a control group. Bohnen, Twjinstra, and Jolles (1992) reported that, on a broad level, postconcussive cognitive complaints were greater in MTBI patients than in controls within 2 weeks of injury. In contrast, overall emotional and vegetative symptoms did not differ between the groups. King, Crawford, Wenden, Moss, and Wade (1995) reported that psychological symptoms such as fatigue, headaches, sleep disturbance, and concentration difficulties were often endorsed by people within 10 days of suffering a MTBI. However, these endorsement levels were not compared with a control group. Levin et al. (1987) assessed somatic, cognitive, and affective symptoms at baseline, 1 month, and 3 months postinjury to MTBI patients at three sites. They found that symptoms for MTBI patients generally declined, though not reaching statistical significance (perhaps related to small sample sizes of 14, 17, and 26), and patient scores were not compared with controls.
In contrast, there is a more substantial literature on long-term complaints after MTBI. Symptom reports in that literature are quite variable, with most MTBI survivors reporting essentially full recovery, but others reporting difficulties (generally referred to as persistent postconcussional syndrome) even years postinjury (Alexander, 1995; Gualtieri, 1995) . Litigation has been associated with post-MTBI complaints, such that litigants do not improve as quickly as nonlitigants, and, indeed, MTBI litigants report more severe effects in some areas than do people with more severe brain injuries (Binder & Rohling, 1996) . Age, education, and gender have been variably related to long-term MTBI symptoms (Binder, 1997; Karzmark, Hall, & Englander, 1995; Kibby & Long, 1996; Rutherford, Merrett, & McDonald, 1979) . Overall, Kay (1993) noted that injury effects may overshadow demo-graphic effects soon after a MTBI, with psychological and demographic factors playing an increased role as time postinjury progresses.
The current study will extend the findings of a study by Paniak, Phillips, Toller-Lobe, Durand, and Nagy (1999) that reported differences on symptom endorsement and severity across three broad subscales of the Problem Checklist (PCL; Kay, Cavallo, Ezrachi, & Vavagiakis, 1995) . The current study will compare the same MTBI patients, within 1 month postinjury, with a matched control group on individual symptom endorsement and severity. One advantage of the current study is that data were collected at Canadian hospitals, where there was no direct cost to patients entering the hospital. As such, data were not as readily confounded with potentially limiting financial concerns [e.g., insurance coverage, socioeconomic status (SES), private vs. public hospital], as would more likely be the case in jurisdictions without universal health insurance.
The hypotheses of the present article are: (1) Demographic variables will correlate minimally with symptoms. Although differences in these demographic variables may correspond with MTBI symptoms many months after the injury (e.g., Binder, 1997) , there is minimal empirical evidence or theoretical rationale in the literature for a connection between these variables and MTBI symptoms early in recovery. (2) Symptom incidence and severity will be greater for MTBI patients than for control participants on a variety of symptoms, but will not differ to the extent that symptoms can be solely relied upon for diagnosis. (3) Variance of symptom reports will be greater in the MTBI group than for the control group, given the wide range of outcomes seen by MTBI survivors even soon after their injury. (4) In terms of specific symptoms, we predict that symptoms most commonly reported in the long term after MTBI (Gasquoine, 1997) -memory difficulties, headache, poor concentration, irritability, dizziness, fatigue, anxiety, depression, sleep disturbance, and diplopia -will have the highest incidence in the MTBI group. (5) Finally, we predict that symptoms previously found to significantly distinguish between MTBI patients and a control group (Dikmen et al., 1986 ) -sleep disturbance, sensitivity to noise, and memory difficulties -will be the symptoms differing most between our groups. Related to the findings from the Dikmen et al. article, we will also explore whether items appearing to differ between the groups, but not attaining statistical significance in their sample (headaches, fatigue, dizziness, difficulty concentrating, and irritability), reach statistical significance in a larger sample.
Method

Participants and procedure
The MTBI group consisted of 118 adults who volunteered to participate in a MTBI treatment study. They were diagnosed according to the Mild Traumatic Brain Injury Committee, Head Injury Interdisciplinary Special Interest Group, American Congress of Rehabilitation Medicine's (1993) MTBI definition and were drawn from consecutive admissions to two hospital emergency wards. A nurse at each of the two emergency wards reviewed new admissions once or twice weekly to identify persons who may have met the American Congress of Rehabilitation's MTBI criteria. Because MTBI diagnostic information was often not evident on hospital emergency documents, the nurses were instructed to use a liberal and possibly overinclusive interpretation of these criteria in deciding whom they would contact. Potential participants were then contacted by telephone and/or letter to ask if they wanted to take part in a study evaluating the efficacy of treatments for concussion. The results of that study are described elsewhere (Paniak, Toller-Lobe, Nagy, & Durand, 1998; Paniak, Toller-Lobe, Reynolds, Melnyk, & Nagy, 2000) .
If interested, the participant telephoned the principal investigator who did a more exacting interview to determine whether the MTBI criteria were met, and whether the person met any exclusionary criteria for the study. Exclusion criteria for the participants included: (1) a history of inpatient treatment for any psychiatric disorder, (2) diagnosis of mental retardation, (3) inability to read fluently in English (based on self-report), (4) history of TBI more severe than a MTBI at any time in their life, (5) a MTBI within 1 year prior to involvement in this study, (6) any ongoing central nervous system disorder, or (7) concurrent pregnancy. If potential participants met the inclusion and exclusion criteria and wanted to participate in the treatment study, they met with the principal investigator within 1 month of injury (mean number of days between injury and first hospital appointment = 12.09; S.D. = 5.84; range = 1-27 days; 96% were within 21 days), at which time the PCL was completed.
The control group consisted of 118 adult participants (staff, students) recruited from university, hospital, and a municipal government office. The same exclusionary criteria were used with control participants as with the MTBI participants. They were group-matched to the MTBI patients on age, sex, years of education, and SES. Control participants completed the PCL and a background questionnaire to obtain necessary data regarding demographic characteristics and exclusionary criteria.
Measures
The PCL from the New York Head Injury Family Interview (Kay et al., 1995) consists of 43 items, each reportedly a common TBI complaint. The three factors reported by Kay et al. (1995) for the PCL are Affective/Behavioral (14 items), Cognitive (nine items), and Physical/ Dependency (eight items). The remaining 12 items include 10 introduced in a later version of the PCL, for which factor analyses were not reported, and two items involving sexual drive, which were omitted by many respondents in their study.
The first part of each PCL item (Problem Experience) indicates whether the person currently experiences the problem, and requires a Yes/No response, with 'Yes' coded as 1 and 'No' coded as 0. The second part of each item (Problem Severity) requires the person to rate on a seven-point scale how much of a problem a complaint endorsed as 'Yes' presents in their daily functioning. Anchors on the Severity portion included ''No Problem'' over one and two, ''Moderate Problem'' over three, four, and five, and ''Severe Problem'' over six and seven. The percentage of items endorsed as 'Yes' on each of the three factors produces a 'Problem Experience' score for each factor. The 'Problem Severity' score for each factor is the average severity score for all of the items on that factor (with 0 assigned to items that were endorsed as 'No' in the Problem Experience section).
SES (Blishen, Carroll, & Moore, 1981) was modified to include scores for the retired, students, homemakers, and those not currently working (Paniak, 1992; Paniak, Shore, Rourke, Finlayson, & Moustacalis, 1992) . Preinjury SES was used for patients, and current SES was used for controls. Table 1 provides demographic information for patient and control groups. No statistically significant ( P < .05) differences existed between the groups on any variable. Effect Sizes (ES), computed as the difference in means divided by the pooled standard deviation (Glass & Hopkins, 1996) , were all negligible (each ES < 0.21).
Results
These demographic variables were then compared using independent t tests, within each group, between respondents who indicated experiencing the item vs. those who did not. Given the number of comparisons that were made, we used a Bonferroni-corrected a (.05/43 items=.00116) rather than the standard .05 significance level. For the control group, only two items differed significantly at this level; people with higher SES reported ''Needing supervision'' (Welch's t(7.67) = 7.42; P < .001) and ''Loneliness'' (Welch's t(94.46) = 4.34, P < .001) less often. 1 (It should be noted that only three control respondents endorsed ''Needing supervision'' positively.) No statistically significant differences were found on any of the items for gender, age, or educational level for the control group, and no items differed for any of these variables for the MTBI group.
Correlations between symptom severity and the demographic variables were generated for each item across each group. Results were similar; for the control group, only two correlations were statistically significant; people with lower education reported higher severity of ''Getting bored easily'' (r = À .31, P = .001) and ''Loneliness'' (r = À .36, P < .001). No effects were found for gender, age, or SES for the control group, and again, no items correlated between demographic variables and severity for the MTBI group at this level of significance. Severity scores were then compared between the groups, and these means are also shown in Table 2 . Across the 43 items, 23 significantly differed between the groups at the .00116 level (all in the direction of higher severity for MTBI patients), with an additional 12 significantly differing at the .05 level (all in the direction of higher severity for MTBI patients, except for ''High sexual drive''). The difference between the groups' severity means was in the expected direction, with the MTBI group reporting significantly higher severity than the nonclinical group [MTBI group severity mean = 1.65, S.D. = 1.28; Control group mean = 0.77, S.D. = 0.65; F(1,234) = 44.026, P < .001, ES = 0.79].
The difference between the groups' variability in symptom severity was tested using Levene's test of variances. This test compared the variances in mean severity level between the groups, and found greater variability in the MTBI group [ F(1,234) = 45.806, P < .001]. A breakdown of the mean severity levels by group is provided in Table 3 . Mean severity was generally low in both groups. Even in the MTBI group, mean severity was reported as moderate or severe (three or higher) for only 17% of MTBI patients (vs. 1% of controls).
A breakdown by group of the number of symptoms experienced is provided in Table 4 . This distribution is similar to that shown in the previous table addressing severity level. Across all 236 participants, mean severity correlated with number of symptoms reported at .90.
To further explore the severity of symptoms, the proportion of participants in each group endorsing at least one symptom in the severe (six or seven) range was analyzed. Twenty-two (19%) of the control participants and 66 (56%) of the MTBI participants rated at least one symptom in the severe range. This difference between the groups was significant (c 2 = 35.08, P < .001). As expected, given the magnitude of this difference, the mean number of items endorsed as severe in the groups also significantly differed [MTBI mean number of items reported at severity 6 or 7 = 3.43, S.D. = 5.80; Control mean = 0.57, S.D. = 1.73; None of the PCL items were endorsed as severe by more than four (3.4%) of the control participants, and as such, were not at a sufficient level to warrant inclusion in the table. Table 5 . The most commonly endorsed symptoms for each group are presented in Table 6 . Seven of the 10 items hypothesized to be commonly reported by the MTBI sample were among the most commonly reported symptoms by our MTBI sample. Of the remaining hypothesized items, dizziness was also commonly reported (58%), with depression (40%) and visual problems (35%) less commonly reported in the MTBI sample. Table 7 lists the symptoms showing the largest difference between the groups. These results did not support our hypothesis that sleep disturbance, noise sensitivity, and memory difficulties would be the items best distinguishing the groups (as per Dikmen et al., 1986) . None of these were among the top eight items in terms of percentage discrepancy between the groups, although each was significantly higher in the MTBI group than in the control group at the .00116 level. Of the five other hypothesized symptoms (headaches, fatigue, dizziness, concentration difficulty, irritability), three were among the items with the largest discrepancies between the groups (fatigue, with a difference of 58%; dizziness, 37%; poor concentration, 29%), with four of the five items statistically significantly differing at the .00116 level between the groups.
A logistic regression was performed to determine which items best distinguished MTBI patients from controls, to determine whether any set of symptoms could sufficiently discriminate persons in these two groups. Of primary interest was the determination of which endorsed symptoms best differentiated between the groups, as experience is more readily evaluated in informal clinical settings than is severity. Therefore, only item experience scores were used in the logistic regression. Noting the need to maintain an appropriate balance between the number of data points and the number of predictors, only the 16 items differing between the groups at the .00116 level were chosen for the stepwise logistic regression (yielding a ratio of roughly 15 participants per item). The ensuing best-fit equation was: 2.6486 Â (Item 4; Doing things slowly) + 2.5740 Â (Item 7; Fatiguing quick- ly) À 1.8336 Â (Item 42; High sexual drive) À 2.3933. The predictor rule was: If this sum is less than zero, the participant is predicted to be in the control group; if greater, then the participant was predicted to be in the MTBI patient group. This equation can reduce to the following rule: If both doing things slowly and fatiguing quickly are endorsed positively, the respondent is predicted to be in the MTBI group; or, if either doing things slowly or fatiguing quickly is endorsed positively and high sexual drive is not, the respondent is predicted to be in the MTBI group; all other respondents are predicted to be in the control group. This prediction was accurate for 81% of the participants (with 92% sensitivity and 70% specificity), yielding a k of 0.62. This indicates that the formula accurately predicted 62% of cases which would not otherwise be predicted correctly by chance. Note that inclusion criteria could be changed by altering the value which the equation would need to exceed to indicate inclusion into either group; changes of this sort would of course increase either the specificity or sensitivity while diminishing the other. However, the current equation is the one which will yield the best possible percentage of correctly placed participants.
Noting that this analysis has artificially high predictive power due to lack of crossvalidation, the data were randomly split into two groups five times, with a stepwise regression function (from the initial 16 variables) determined for one-half of the data and then crossvalidated by assessing the equation's accuracy for the other half. In these equations, Items 4 and 7 were included all five times, Item 42 was included three times, and Item 39 (Changes in appetite) was included once. These frequencies lend support to the initial overall equation due to the similarity of items found in the equations. The five cross-validation analyses yielded accuracies ranging from 76% to 82% across the five samples, with a mean of 78% and a k of 0.55 across the samples. These accuracy levels, as expected, were generally slightly lower than the accuracy found when using the initial overall sample, and provide evidence that the equation generated by the overall sample would inaccurately classify approximately 20-25% of people into either the MTBI or non-MTBI group.
Discussion
As predicted, demographic variables were not found to correlate significantly with symptom complaints. Our hypotheses that symptom experience and severity would be higher for MTBI patients than for control group participants were supported, as was our hypothesis that this difference would not be sufficient to allow a conclusive diagnostic decision on the basis of symptom reports alone. Our hypothesis that the variance of symptoms would be greater in the MTBI group than the control group was also supported. Related to this point, it was striking that although a minority of MTBI patients endorsed moderate to severe problems overall, most reported mean symptomatology in the ''No Problem'' range.
Hypotheses regarding symptoms seen most frequently in the MTBI group received mixed support. The most commonly reported symptoms were fatigue, headaches, forgetfulness, sleep problems (each as hypothesized), and doing things slowly (not hypothesized). However, our hypotheses regarding the specific symptoms which would differ the most between the MTBI and control groups were not generally supported. Nonhypothesized items such as doing things slowly, fatigue, poor balance, difficulty thinking clearly, and dizziness differed the most between the groups.
An intriguing finding from these analyses was the heterogeneity of symptom reports across individuals in the MTBI group. The variability in mean severity across participants in the MTBI group was much larger than that found across participants in the control group. To provide insight regarding potential reasons for this variability, symptom report was correlated with a measure of overall nonbrain physical injury severity, Injury Severity Score (ISS; Association for the Advancement of Automotive Medicine, 1990). However, overall nonbrain physical injury severity as reflected by ISS had no relationship to symptom report within 1 month of the injury (r = À .02, P > .5). This might have been because our patients generally had relatively mild, if any, concurrent nonbrain injuries, leading to a relatively restricted range of ISSs.
Comparisons were also made between MTBI survivors who were and were not taking psychotropic medication prior to the accident (14 of 118 were), between survivors who were and were not taking analgesic, neurologic, or psychopharmacological medication after the injury (35 of 118 were), and between survivors who were and were not taking any medication at all after the injury (65 of 118 were). None of these comparisons yielded significantly ( P > .1 for each comparison) different symptom experience or severity scores between the groups, with experience ES of 0.01, 0.31, and 0.21, respectively, all in the direction of increased symptom experience for people taking medication. However, it should be noted that the above analyses were relatively crude, given that potentially important information such as dosage levels of medications were not routinely available for analysis.
A substantial gap in symptom report between people seeking/receiving compensation (i.e., either through a litigation attempt, Workers' Compensation claim, sick leave, or disability leave) and those not was found (ES = 0.45, P = .024), such that compensation seekers/ receivers reported a higher number of symptoms. Though seeking or receiving money had some association with increasing the variability of symptom reports for the overall MTBI group, it is not sufficient on its own to explain the high variability. Perhaps some aspects of brain injury severity not currently measured or observed explain much of the increased variability. Indeed, Kibby and Long (1996) argue that the recommended definition of MTBI employed in the current study is too broad, and others have found empirical evidence for differences across GCS scores ranging from 13 to 15 (e.g., Culotta, Sementilli, Gerold, & Watts, 1996) . Hsiang, Yeung, Yu, and Poon (1997) recommend a more refined definition of MTBI, splitting MTBI survivors into a mild group and a ''high-risk'' group based on GCS scores and radiographic abnormalities. A third hypothesis to explain greater variability in symptom reports for the MTBI group may come from the interaction of premorbid personality characteristics with the MTBI. Specifically, persons already experiencing stress or psychological difficulty may react to the injury significantly worse than people without a high level of other stressors (Kay, 1993) .
The current results replicated previous research regarding the commonality of symptom reports by both MTBI and control samples (e.g., Fox, Lees-Haley, Earnest, & DolezalWood, 1995; Gasquoine, 1997) . For example, headaches were reported by 78% of our MTBI patients and 55% of control participants. As well, symptoms generally considered related to MTBI (fatigue, dizziness, distractibility, irritability) were all endorsed by over 20% of controls.
The symptom experience figures for our two groups, to some degree, contrast symptom reports described in previous literature as being indicative of a MTBI. In his review article, Gasquoine (1997) reported that the five symptoms most commonly reported as being experienced by MTBI survivors in previous postconcussive research (reported in at least eight of the nine studies) were headache, memory loss, poor concentration, irritability, and dizziness. In our MTBI sample, these were reported as the 2nd, 3rd, 6th, 8th, and 13th most common symptoms. In our control group, however, these symptoms were endorsed by 58%, 47%, 35%, 47%, and 22%, respectively, indicating substantial overlap between the groups on these symptoms.
The current results also extend the Dikmen et al. (1986) findings. As we had larger samples to compare, we correspondingly found more symptoms differing at a statistically significant level than did Dikmen et al. Given the commonality in symptom reports between MTBI survivors and controls, the need for a sufficiently large sample to detect statistically significant differences when they indeed exist is crucial to minimize the likelihood of Type II error (i.e., obtaining null findings when differences between the groups exist in the population).
The lack of symptom specificity, particularly when combined with the finding that a logistic regression was unable to weight a set of symptoms to definitively distinguish MTBI patients from normal controls, even within 1 month of injury, highlights the importance of relying on information other than symptom complaints in diagnosing MTBI. As noted previously, the most accurate equation for distinguishing MTBI participants from control participants yielded a specificity of only 70%; presumably, this value would be lower if patients without a diagnosable MTBI, coming to a physician's office following a hit on the head, were compared to those with a diagnosable MTBI. As well, the current results, which suggest caution should be used in attributing so-called postconcussive symptoms to MTBI, do not adequately offer the more stringent and clinically relevant test of distinguishing MTBI from other issues (e.g., pain, medication side-effects, or emotional problems; Satz et al., 1999) . For instance, Iverson and McCracken (1997) note that fatigue, the symptom most commonly reported by our MTBI patients, is also the most commonly reported symptom for patients with pain. Pain medication side-effects often include sedation and cognitive problems, an important issue given the commonality with which musculo-skeletal complaints accompany MTBI (Paniak et al., 1999) . Doing things slowly could be seen as akin to psychomotor retardation, one of the DSM-IV (American Psychiatric Association, 1994) criteria for depression. The same may be said for several other symptoms differing between the groups (e.g., poor concentration, fatiguing quickly, sleep disturbance).
Very interesting was that the symptom with the highest absolute difference between the groups (i.e., ''Doing things slowly'') has been rarely reported upon in previous self-report symptom research. Indeed, it had not been previously noted as a measured symptom (specifically noted in none of the nine studies reported in Gasquoine's MTBI symptom review), though other items which would correspond with slow performance (e.g., poor concentration, fatigue), had been previously noted. As well, consistent with our findings, problems with speeded performance have been repeatedly noted on neuropsychological testing soon after MTBI (e.g., Binder, 1986; Hugenholtz, Stuss, Stethem, & Richard, 1988; Stuss et al., 1989) . A potential line of future research could involve the correspondence between patients' self-reports soon after a MTBI and neuropsychological performance.
Despite the frequency of some symptoms commonly reported by MTBI survivors, the mean severity reported by this group was typically quite low. This is perhaps surprising so soon following the injury. However, our findings may still overestimate the severity and presence of symptoms, as we used a hospital-based sample, and many people with a MTBI do not ever go to a hospital (Frankowski, Annegers, & Whitman, 1985) . The relative infrequency of high severity in the MTBI group is also surprising, given the reported commonality of long-term complaints by some persons following a MTBI (Alexander, 1995) . Our findings indicate the possibility that the minority of people reporting symptoms at a moderate or severe level soon after MTBI may be at elevated risk for poor long-term outcome, though this remains to be proven.
Several limitations of the current study should be noted. Comparisons were made between our clinical and nonclinical samples; however, it would still be useful to compare a clinical MTBI sample against a clinical non-MTBI sample (e.g., whiplash, acute stress disorder, or recently injured orthopedic patients). This comparison could provide further information regarding discrimination of symptoms as being secondary to a brain injury as opposed to another injury-or psychologically-related cause. Satz et al. (1999) argue that there is no sufficient evidence to state that a mild TBI, in the absence of other related injuries or other factors, can cause the symptoms of persistent postconcussive syndrome. A second limitation in the current study was the use of only a single sample. Single samples can provide demographically unusual groups (for instance, our sample was 52% female, in contrast with gender distributions from other studies using a preponderance of males). Though it should be noted that demographic variables did not correlate either clinically or statistically significantly with the symptoms of interest, there may nonetheless have been other unmeasured factors unique to our sample. As such, replication of the current findings in another context would be useful.
The current study raises a variety of issues requiring further research. For instance, further research comparing a MTBI sample with a control group across time could yield information as to the sensitivity of the PCL to persistent complaints. Further study is also necessary regarding the role of premorbid personality and demographic factors. In the current study, demographic factors generally did not correspond with symptom endorsement. This is in contrast to previous reports of a correspondence between demographic variables and specific symptoms in the long term (e.g., Binder, 1997) . Perhaps the difference between those studies and the current study was the length of time postinjury that the symptom was assessed. In our sample, soon after injury, the neurologic effects of some MTBI may initially overpower or outweigh other variables' influence. Demographic variables may become more important later on, once they are no longer masked by injury-related variables. Kay (1993) noted that ''Certain personality styles may be more susceptible to catastrophic reactions to mild cognitive impairment' ' (p. 75) . Given the substantial variability of symptom endorsement in the MTBI group and our generally null finding of an association between our demographic variables and symptom report, are there other individual factors which account for this relatively large variance? Such individual differences could emanate from preinjury differ-ences in mental health, personality factors, or from litigation-related factors (e.g., Youngjohn, Burrows, & Erdal, 1995) .
Overall, it is surprising that patient complaints soon after MTBI have been so rarely studied in the past. The present research provides a partial baseline for understanding patient complaints soon after MTBI. It also raises important issues for future research. These include gaining a better understanding of reasons for the high variability in patient complaints soon after MTBI, and an understanding of the relationship between short-term and long-term complaints.
